Cost-benefit analysis of deceased donor organ transplantation: an economic evaluation

This economic evaluation of deceased donor organ transplantation in the UK concludes that while kidney transplants are cost-saving compared to dialysis, heart and liver transplants are cost-effective within standard thresholds, whereas lung transplants remain the least cost-effective option.

The Gist

Imagine the National Health Service (NHS) is a giant, busy household trying to keep everyone healthy. Every year, about 4,500 people in the UK get a "spare part" installed—a new kidney, liver, heart, or lung from someone who has passed away. This surgery is a miracle; it saves lives and lets people get back to living normally. But, like any major home renovation, it comes with a hefty price tag for the household budget.

This paper asks a simple but crucial question: Is spending all that money on the surgery actually a good deal for the household, or does it cost more than just leaving the patient with their failing organ?

To answer this, the authors acted like financial detectives. They compared two scenarios for every patient:

1. The Transplant Path: The patient gets the new organ, pays for the surgery, and lives a longer, healthier life.
2. The "No Transplant" Path: The patient stays on the waiting list, gets sick, and relies on expensive, long-term treatments (like dialysis for kidneys) until they pass away.

Here is the breakdown of their findings, explained with some everyday analogies:

1. The Kidney: The "Money-Saving Superhero"

The Verdict: It saves money.
Think of a kidney transplant like buying a high-quality, energy-efficient washing machine. The upfront cost of buying and installing it is high. However, if you don't buy it, you have to keep paying for a very expensive, broken-down service (dialysis) that runs 24/7 for the rest of your life.

• The Math: The study found that for every kidney transplant, the NHS actually saves about £220,000 over the patient's lifetime.
• The Takeaway: If we can find more kidneys to transplant, the NHS doesn't just save lives; it literally puts money back in its pocket by stopping the need for endless dialysis treatments.

2. The Heart and Liver: The "Worthwhile Investment"

The Verdict: Good value for money.
Imagine these transplants are like renovating a house to fix a dangerous roof. It costs a lot of money upfront, but it stops the house from collapsing and saves you from having to live in a tent forever.

• The Math: These transplants cost the NHS about £17,000 to £18,000 for every extra year of "quality life" gained.
• The Context: In the UK, the government generally considers anything under £20,000–£30,000 per year of life to be a "good deal." So, heart and liver transplants are right in that sweet spot. They are a solid investment that pays off in human lives.

3. The Lung: The "Expensive Gamble"

The Verdict: It's the most expensive option.
Think of a lung transplant like trying to fix a very old, complex engine that is prone to breaking down again quickly. The surgery is incredibly expensive, the recovery is tough, and the new engine doesn't last as long as the others.

• The Math: This costs over £50,000 for every extra year of quality life gained.
• The Context: This is above the usual "good deal" threshold. While it still saves lives and is often considered worth it in a moral sense, purely from a strict budget perspective, it is the least efficient use of funds compared to the other organs.

The "Waiting List" Mystery

The study also looked at what happens if you don't get the organ.

• For Kidneys: Without a transplant, patients stay on dialysis for years. This is like paying a monthly subscription to a service that keeps you alive but doesn't let you enjoy life. It's very expensive for the NHS.
• For Lungs and Hearts: Without a transplant, patients often get very sick very quickly. Because they don't live as long without the organ, the NHS spends less money on their care before they die. This makes the transplant look "more expensive" in the math because the alternative (doing nothing) was cheaper, even though the patient died sooner.

The Big Picture: Why This Matters

The authors conclude that not giving a transplant to someone who needs one isn't "free." It just shifts the cost to other expensive treatments (like dialysis) and results in shorter, lower-quality lives.

The "Sunk Cost" of Organ Retrieval:
The study also noted that the cost of finding and retrieving the organ (the donor's surgery and transport) happens whether the organ is used or not. If we treat that cost as "already spent," the math for heart and liver transplants looks even better, making them an even clearer "good deal."

The Bottom Line

• Kidneys: Transplanting them is a financial win for the NHS and a life win for patients. We should try to get more of them.
• Hearts & Livers: These are solid investments that save lives at a reasonable cost.
• Lungs: These are the most expensive to do, but they still save lives. The challenge is finding ways to make them last longer or cost less.

In short: The study tells us that organ transplantation isn't just a medical miracle; it's also a smart financial strategy for the healthcare system, especially for kidneys. By fixing the "broken parts," the system avoids the much higher cost of keeping the "broken machine" running with expensive, temporary patches.

Technical Summary

1. Problem Statement

The United Kingdom faces a critical shortage of organs for transplantation, with nearly 8,000 people on the active waiting list as of July 2025. The unmet demand results in significant mortality (463 deaths in the 2024/25 period) and high ongoing healthcare costs, particularly for kidney failure patients requiring dialysis (estimated at £34,000 per patient annually). While organ transplantation is life-extending, it involves substantial upfront costs. There is a need for a comprehensive, multi-organ economic evaluation to determine if the lifetime costs of transplantation are offset by the savings from avoiding end-stage organ failure treatments (counterfactuals) and to inform policy decisions regarding organ utilization strategies, such as the proposed Assessment and Recovery Centre (ARC).

2. Methodology

The study employs a lifetime cost-effectiveness analysis comparing two pathways for adult patients with end-stage organ failure:

• Transplant Path: Receiving a deceased donor organ (Kidney, Liver, Heart, or Lung).
• Counterfactual Path: Remaining on the waiting list without a transplant until death.

Key Modeling Components:

• Scope: Focused on NHS healthcare costs and patient Quality-Adjusted Life Years (QALYs). Wider societal impacts (e.g., employment, family burden) were excluded.
• Discounting: Costs were discounted at 3.5% and health benefits (QALYs) at 1.5% annually, in line with HM Treasury's Green Book.
• Data Sources:
  • Survival: Modeled using NHSBT organ-specific reports (1-year and 5-year survival) and median survival data. Waiting list survival was estimated via clinician judgment based on NHSBT data, as direct waiting list survival data was deemed biased (excluding those removed for deterioration).
  • Costs: Derived from the NHS National Cost Collection (2022-2025 averages), Hospital Episodes Statistics (HES), and the British National Formulary (medication).
  • Utilities: Health-related quality of life weights were sourced from literature (references [10] and [11]).
• Specific Adjustments:
  • Kidney: Counterfactual costs included dialysis, transport, and high-cost drugs (erythropoietin).
  • Heart: Separate analyses for non-urgent, urgent, and super-urgent lists.
  • Lung: Separate analyses for non-urgent and urgent lists (super-urgent sample size was too small).
  • Organ Retrieval: A cost of £74,580 per donor and £29,050 per transplant was included, though sensitivity analyses explored scenarios excluding these "sunk costs."

Sensitivity Analysis:
A one-way sensitivity analysis was performed, varying key parameters (survival, costs, QALYs) by ±25% (±50% for survival without transplant) to test the robustness of the results.

3. Key Contributions

• Comparative Multi-Organ Analysis: Unlike previous studies focusing on single organs, this paper provides a unified economic evaluation across four major solid organ transplants (Kidney, Liver, Heart, Lung) using a consistent methodology, allowing for direct comparison of cost-effectiveness.
• Donor-Level Perspective: The study calculates the aggregate value per donor, estimating that a single donor (yielding an average of 1.69 kidneys, 0.22 lungs, 0.14 hearts, and 0.60 livers) generates a net saving of approximately £203,000 and 18.1 QALYs for the NHS.
• Policy-Relevant Thresholds: The analysis explicitly tests results against multiple cost-effectiveness thresholds, including the NICE standard (£20k–£30k/QALY), the DHSC opportunity cost threshold (£15k/QALY), and the HM Treasury high-value threshold (£70k/QALY).
• Counterintuitive Insight: The study highlights that for heart and liver transplants, cost-effectiveness improves if the "survival without transplant" is better (i.e., the patient lives longer without the organ). This is because a longer pre-transplant survival increases the baseline costs of the counterfactual (dialysis/care), which are then averted by the transplant, thereby increasing the net savings/QALY gain ratio.

4. Results

Cost-Effectiveness per Organ (Central Estimates):

Organ	Incremental Cost	Incremental QALYs	Cost per QALY Gained	Verdict
Kidney	-£223,619 (Cost Saving)	6.07	-£36,856	Dominant (Cost Saving)
Liver	£169,421	9.43	£17,963	Cost-effective (NICE threshold)
Heart (Non-Urgent)	£128,665	7.59	£16,944	Cost-effective (NICE threshold)
Heart (Urgent)	£140,005	8.39	£16,685	Cost-effective (NICE threshold)
Heart (Super-Urgent)	£149,575	8.47	£17,650	Cost-effective (NICE threshold)
Lung (Non-Urgent)	£245,740	4.59	£53,541	Not Cost-effective (at standard thresholds)
Lung (Urgent)	£280,432	5.63	£49,818	Not Cost-effective (at standard thresholds)

• Kidney Transplants: Are cost-saving. The lifetime cost of a transplant is ~£220,000 lower than the cost of dialysis and associated care. With ~2,300 adult deceased donor kidney transplants annually, this equates to over £500 million in lifetime savings for the NHS.
• Heart and Liver Transplants: Are highly cost-effective, falling well within the NICE threshold of £20,000–£30,000 per QALY and close to the DHSC £15,000 threshold.
• Lung Transplants: Are the least cost-effective, with a cost per QALY exceeding £50,000. This is driven by high post-transplant mortality and lower costs associated with the poor survival of patients on the waiting list.
• Excluding Retrieval Costs: When organ retrieval costs are treated as sunk costs (excluded), the cost-per-QALY for all organs improves, though lung transplants remain above standard thresholds.

Sensitivity Analysis Findings:

• Kidney transplants remain cost-saving under all tested scenarios.
• Lung transplants remain the least cost-effective.
• Heart transplant cost-effectiveness is highly sensitive to assumptions regarding survival without a transplant.
• Liver transplant results are comparatively stable across parameter variations.

5. Significance and Implications

• Economic Justification for Expansion: The analysis provides robust evidence that increasing the supply of deceased donor organs, particularly kidneys, will result in significant net savings for the NHS while improving patient survival and quality of life.
• Strategic Prioritization: The findings support the Department of Health and Social Care's (DHSC) focus on maximizing organ utilization (e.g., via the Assessment and Recovery Centre). Increasing kidney availability is a "win-win" for both clinical outcomes and fiscal sustainability.
• Policy Thresholds:
  • Under the NICE threshold (£20k–£30k/QALY), Kidney, Heart, and Liver transplants are cost-effective; Lung transplants are not.
  • Under the DHSC opportunity cost threshold (£15k/QALY), Heart and Liver transplants are borderline or slightly outside the threshold in central estimates but become cost-effective in many sensitivity scenarios or if retrieval costs are excluded.
• Environmental Impact: The paper notes that kidney transplantation supports the NHS Net Zero strategy by reducing the environmental footprint associated with long-term dialysis.
• Limitations & Future Work: The study relies on utility weights over 20 years old and assumes an "average patient." Future research should incorporate pediatric transplants, living donors, and broader societal benefits (e.g., return to employment) to refine the economic model.

In conclusion, the paper demonstrates that while lung transplants currently struggle to meet standard cost-effectiveness criteria, kidney, heart, and liver transplants represent high-value interventions for the NHS, with kidney transplants offering a unique opportunity to reduce overall healthcare expenditure.